New study finds defensive medicine costs the USA $45 billion

20 September 2010

A study reported in the 2010 issue of Health Affairs has found that costs related to medical liability account for more than $55 billion a year or 2.4% of the total costs to the US health care system. According to the study, approximately 80%, or $45 billion of these costs are the result of defensive medicine, procedures performed to avoid unnecessary litigation.

Commenting on the report, Lisa Maas, executive director of Californians Allied for Patient Protection (CAPP), issued "Common sense dictates that if health care practitioners are looking over their shoulders and constantly worried about getting sued, they will take action to cover themselves. These actions have societal costs and this recent study found that the costs impact us by more than $45 billion per year. Meritless law suits do not result in better care, just more dollars spent on defensive medicine, unnecessary tests and litigation costs that drive up the cost of healthcare for everyone.”

She continued: "The study demonstrates that, if national medical liability tort reform were implemented to limit meritless law suits, it could produce a national health care savings of tens of billions of dollars. That is a significant savings. It would free up these funds to care for the uninsured, make insurance more affordable, or provide new dollars for more research.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical